We have a number of exciting and innovative cannabinoid research projects across several species generating the evidence needed to improve healthcare in both humans and animals. We are actively involved in, or sponsor, projects with different Universities under relevant U.K. Home Office licenses. These include ‘Seed genetics and phenomics’, ‘Fractionation’, ‘Process engineering & optimisation’, Preclinical trials into the comparative effects and efficacy of cannabinoids in the treatment of ‘Anxiety’; ‘Dependence and substance use’, ‘Infection, inflammation and immunity’ and ‘Pain and nausea’.
Peer reviewed publications will be made available in due course.
We invite enquiries from academic teams and partners who need reliable and consistent supplies of high quality Cannabinoid products manufactured utilising current ‘best practices’ found within the Active Pharmaceutical Ingredients (API) industry.
Telephone: +44 0151 482 9160
Summary: Preliminary evidence suggests that CBD reduces craving for opiates in humans.
The American Journal of Geriatric Psychiatry, April 2021.
Summary: Ongoing study of high-CBD/low-THC sublingual solution. Results awaited.
Psychopharmacology, April 2021.
Summary: Cannabis may relieve stress in people who expect to benefit. People who already believed CBD to have anxiolytic qualities reported diminished anxiety.
Pubmed, February 2021.
Summary: A summary of preclinical literature on anxiolytic and antidepressant effects of cannabidiol.
Journal of Transnational Medicine, October 2020.
Summary: This recent overview provides a summary of all studies to date in humans and animals where cannabis extracts, THC and CBD have been investigated for their effects on anxiety.
Pubmed, National Library of Medicine, October 2020.
Summary: This case report describes a 20 year old man with social anxiety disorder and attenuated psychotic symptoms which had not responded to conventional treatment with antidepressants and psychological therapy. The man experienced symptom relief when treated with cannabidiol in doses between 200 and 800 mg/day for 6 months.
Pubmed, October 2020.
Summary: This paper gives further details about the mechanisms by which endocannabinoids may regulate mood.
Journal of Anxiety Disorders, 2021.
Summary: Improving the quality of studies on anti anxiety effects of cannabinoids. Good overview of studies on anxiety conducted to date and suggestions for how the evidence could be strengthened.
Aging, April 2021.
Summary: How could cannabidiol reduce oxidative stress and help people with Parkinsons disease? CBD can target the WNT/β-catenin pathway by downregulating GSK-3β in preclinical studies resulting in relief of oxidative stress and inflammation.
Frontiers in Pharmacology, April 2021.
Summary: Overview of lab studies on cannabis and inflammatory bowel disease. Cannabis may potentially affect gastrointestinal permeability and immune activation – the clinical benefits of this are uncertain.
Pubmed, November 2020.
Summary: Preliminary data showing efficacy and patients preferred the formulation to placebo.
Journal of Pain, June 2021.
Summary: Most people who substituted cannabinoids for conventional pain medication found that they could reduce or stop medication. A study of people who were taking CBD for fibromyalgia (n=878) found that 72% had replaced their conventional medications with CBD. The main reasons for substituting being fewer side effects and better symptom management. CBD-Cannabis (Containing >0.3% THC) was found to be the most successful and occured the most substitutions.
PAIN Journal, March 2021.
Summary: CB1 and CB2 agonists can reduce pain in inflammatory and neuropathic pain models whereas cannabidiol may only reduce pain behaviour in neuropathic models.
Cannabis and Cannabinoid Research, 2021.
Summary: This study showed no overall reduction of pain on a group-wide basis, however individuals reported varying results.
Sleep Research Society, 2021.
Summary: Cannabinoid extract helps people with insomnia to achieve higher quality sleep while also allowing them to sleep for longer. Randomized trial of insomnia patients treated with CBD reported lower sleep onset latency and an average of one hour extra total sleep time, as well as a higher quality of sleep upon taking CBD.
Frontiers in Psychiatry, February 2021.
Summary: Guidance for designing new studies on the effectiveness of cannabinoids for treating substance use disorders. Useful information about the outcomes to use for clinical trials. Paper suggests that genetic and phenotypic biomarkers of endocannabinoid system activity could be used to predict response.
JAMA Neurology, December 2020.
Summary: This randomised placebo controlled trial evaluated whether cannabidiol was effective in reducing the number of seizures in people with tuberous sclerosis. All participants were already taking standard treatments for epilepsy. The number of seizures was reduced by about half in people taking 25mg/kg/day of cannabidiol and by a similar amount in those taking 50mg/kg/day. Common unwanted effects were diarrhoea and drowsiness which were more frequent in those taking the higher dose of cannabidiol.